Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Gleibner E, Muhlbacher A, Kieseier B. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Ther Adv Neurol Disord. 2016 Mar;9(2):95-104. doi: 10.1177/1756285615622736.
Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089
Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Carson RT, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing chronic constipation symptom severity and change: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 6; 24(Suppl. s2):180.
Spiegel BMR, Locke G, Kurtz CM, Williams VSL, Nelson LM, Carson RT, Currie MG, Schneier HA, Johnston JM. Clinically meaningful change benchmarks for IBS-C symptoms developed using data from two phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep; 24(s2):35.
Nelson LM, Williams VSL, Carson RT, Baird MJ, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBSC): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):106. doi: 10.1111/j.1365-2982.2012.01997.x
Carson RT, Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):179.
Mangel AW, Fehnel SE. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists. Neurogastroenterol Motil. 2008 Oct 1;20(10):1086-93.
Dorazio P, Keininger DL, Abetz L, Coombs JH, Copley-Merriman K, Bury-Maynard DP, Hsu MA. Comparing patient and nurse perspectives on cancer treatment: results from a qualitative study. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; September 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 Sep; 22:778.
Coombs JH, Abetz L, Keininger DL, Earle CC, Copley-Merriman K, Hsu M-A, Bury-Maynard DP. Development of the Cancer Chemotherapy Satisfaction Questionnaire (CCSQ): part I: item-generation and content validity testing. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:545.
Clark M, Copley-Merriman K, Coombs JH, Von Pawel J, Koschel G, Pauer LR. Patient reported outcomes (symptoms, functioning, and quality of life [QOL]) in a randomized Phase II study of CI-994 plus carboplatin and paclitaxel (C/T) vs placebo (PBO) plus C/T in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:687.